Oppenheimer lowered the firm’s price target on TransMedics (TMDX) to $125 from $200 and keeps an Outperform rating on the shares following quarterly results. The firm notes TransMedics reported quarterly revenue of $108.8M, below its/consensus $117.1M/$115.0M estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target lowered to $109 from $169 at Canaccord
- TransMedics price target lowered to $150 from $200 at Baird
- TransMedics reports Q3 EPS 12c, consensus 29c
- TransMedics backs FY24 revenue view $425M-$445M, consensus $444.36M
- TransMedics Group options imply 19.0% move in share price post-earnings